新功能、新界面、新体验,扫描即可下载生物谷APP!
首页 » BIOON报道 » Applied Proteomics融资2800万美元推出结肠癌检测方法

Applied Proteomics融资2800万美元推出结肠癌检测方法

来源:生物谷 2013-08-24 23:04

2013年8月24日讯 /生物谷BIOON/ --位于圣迭戈的Applied Proteomics公司通过刚刚结束的第三轮融资募集2800万美元用于推出其第一个诊断检测结肠癌的检测方法。而就在去年,公司刚刚结束了总额达2250万美元的第二轮融资。公司花费多年开发基于检测蛋白质差异的诊断技术。Applied Proteomics公司表示其开发的方法能够比现有方法更早检测到发病征兆,大大节省了医疗成本。公司CEO表示这种检测方法市场广阔,今后公司将继续开发基于蛋白质检测技术的疾病监测方法。(生物谷Bioon.com)

详细英文报道:

San Diego's Applied Proteomics is gearing up to launch its first diagnostic tests, and now the company has $28 million to get it there thanks to a just-closed Series C.

The round, led by Malaysia's Genting Berhad and including existing investors Domain Associates and Vulcan Capital, follows a $22.5 million Series B closed last year.

Applied Proteomics has spent years developing molecular diagnostic tools that detect the earliest stages of disease by reading conversations between bodily proteins, an approach the company says could help identify ailments faster than current methods and save millions of dollars in healthcare costs. Now, with another $28 million in the bag, Applied Proteomics can move toward commercialization, starting with a blood test for pre-cursors to colorectal cancer, CEO Peter Klemm said.

"The market potential is huge," Klemm told FierceBiotech Editor-in-Chief John Carroll, declining to give any projections on actual sales. There's more validation work to be done, he explained. Current guidelines recommend a colonoscopy once every 10 years for people over the age of 50, but the CEO notes that there are 44 million Americans who ignore that recommendation.

A test that flags the risk of colon cancer could motivate them to get a colonoscopy, and insurers would benefit by shifting patients into preventive programs rather than waiting for cancer to advance.

In the meantime, Applied Proteomics is building a high-capacity lab to prepare for all the tests it'll have to process once it gets on the market, and the company will pour some of its fundraising haul into R&D for more protein-based diagnostic tools targeting chronic conditions.

Klemm came aboard as Applied Proteomics closed its Series B in February 2012, following stints as CEO of Predictive Biosciences and chief of GeneOhm Sciences before its 2002 acquisition by Becton Dickinson ($BDX).

 

温馨提示:87%用户都在生物谷APP上阅读,扫描立刻下载! 天天精彩!


相关标签

最新会议 培训班 期刊库